Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Recursion Pharmaceuticals ( (RXRX) ) just unveiled an update.
On June 10, 2025, Recursion Pharmaceuticals announced a 20% reduction in its workforce and infrastructure as part of a streamlined operating strategy. This move is expected to extend the company’s cash runway into the fourth quarter of 2027, despite incurring approximately $11 million in charges related to severance and employee benefits in 2025. The company anticipates cash burn to be under $450 million in 2025 and less than $390 million in 2026, with potential cash inflows exceeding $100 million from milestone payments by the end of 2026. These strategic changes aim to optimize Recursion’s financial position and operational efficiency, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (RXRX) stock is a Hold with a $8.00 price target. To see the full list of analyst forecasts on Recursion Pharmaceuticals stock, see the RXRX Stock Forecast page.
Spark’s Take on RXRX Stock
According to Spark, TipRanks’ AI Analyst, RXRX is a Neutral.
Recursion Pharmaceuticals’ stock score is primarily influenced by its robust revenue growth and strategic partnerships, which provide a basis for cautious optimism. However, persistent profitability issues and valuation challenges, compounded by technical indicators pointing to potential volatility, temper the overall outlook.
To see Spark’s full report on RXRX stock, click here.
More about Recursion Pharmaceuticals
Recursion Pharmaceuticals operates in the pharmaceutical industry, focusing on technology-driven drug discovery and development. The company leverages its proprietary Recursion Operating System (OS) to advance drug candidates, particularly in oncology and rare diseases, and engages in partnerships to enhance its research and development capabilities.
Average Trading Volume: 21,798,477
Technical Sentiment Signal: Sell
Current Market Cap: $2.23B
For detailed information about RXRX stock, go to TipRanks’ Stock Analysis page.